Condition

Plaque Psoriasis clinical trials and research

• 21Clinical trials
• 30Countries

Newest Plaque Psoriasis clinical trials

All recruiting trials (21)

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

• D-2570 oral treatment for adults with moderate to severe plaque psoriasis

  This trial tests whether the oral medicine D-2570 helps adults with moderate to severe plaque psoriasis compared with placebo and an approved oral drug.

  Recruiting Phase 3 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07326813

• ICP-332 versus placebo for moderate-to-severe plaque psoriasis

  This will test whether ICP-332 helps adults with moderate-to-severe plaque psoriasis compared with a placebo.

  Recruiting Phase 2 Beijing InnoCare Pharma Tech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07251998

• Long-term zasocitinib treatment for children and teenagers with plaque psoriasis

  This long-term study will see if the medicine zasocitinib is safe and helps children and teenagers (ages 4 to under 18) with moderate-to-severe plaque psoriasis.

  Recruiting at 37 sites Phase 3 Takeda · Chula Vista, California and 38 other locations · NCT07250802

• TYK2 inhibitor for adults with moderate to severe plaque psoriasis

  This will test whether a TYK2 inhibitor taken for 12 weeks helps adults with moderate to severe plaque psoriasis improve their skin and symptoms.

  Recruiting Usynova Pharmaceuticals Ltd. · Shanghai · NCT07234591

• D-2570 treatment for moderate to severe plaque psoriasis

  This trial will try D-2570 versus placebo to see if it helps and is safe for people with moderate to severe plaque psoriasis.

  Recruiting Phase 3 InventisBio Co., Ltd · Beijing, Beijing Municipality · NCT07130604

• CS32582 for moderate to severe plaque psoriasis

  This trial will test whether the oral medicine CS32582 helps adults with moderate to severe plaque psoriasis compared with a placebo.

  Recruiting Phase 1/2 Chipscreen Biosciences, Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT07129382

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

• Risankizumab for improving quality of life in adults with moderate-to-severe plaque psoriasis

  See if risankizumab improves quality of life for adults with moderate-to-severe plaque psoriasis treated in routine clinical care.

  Recruiting at 82 sites AbbVie · Calgary, Alberta and 83 other locations · NCT07039110

• Testing UA026 oral tablets in healthy adults and adults with moderate to severe plaque psoriasis

  We will test whether UA026 tablets are safe, how the body processes them, and whether food changes absorption in healthy adults and adults with moderate to severe plaque psoriasis.

  Recruiting Phase 1 Usynova Pharmaceuticals Ltd. · Hangzhou, Zhejiang · NCT07038720

• Observational study on patients switching to a biosimilar treatment for Crohn's disease and plaque psoriasis

  This study is testing if switching to a new biosimilar treatment for Crohn's disease and plaque psoriasis helps patients stay in remission and feel satisfied with their care.

  Recruiting Celltrion HealthCare France · Amiens · NCT06997055

• Deucravacitinib for teens with moderate to severe plaque psoriasis

  This trial will test whether deucravacitinib helps teens with moderate to severe plaque psoriasis while tracking safety and drug levels.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 132 other locations · NCT06979453

• Comparing the effectiveness of deucravacitinib and apremilast for plaque psoriasis in adults in Japan

  This study is testing whether a new medication called deucravacitinib works better than apremilast for adults with plaque psoriasis in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT06382987

• Improving Psoriatic Arthritis Screening for Patients with Plaque Psoriasis

  This study is testing a new way to help doctors spot psoriatic arthritis earlier in patients with plaque psoriasis by adding extra questions and images to a screening tool.

  Recruiting at 30 sites Novartis · Calgary, Alberta and 29 other locations · NCT06382051

• Switching to Tildrakizumab for Moderate to Severe Plaque Psoriasis

  This study tests if switching patients with moderate to severe plaque psoriasis to a new medication called tildrakizumab can improve their skin condition and quality of life.

  Recruiting Almirall, S.A. · Graz, Styria · NCT06030076

• Collecting samples from people with skin conditions and healthy volunteers

  This study is collecting samples from people with different skin conditions and healthy volunteers to see how their biology differs and learn more about these conditions.

  Recruiting Innovaderm Research Inc. · Montreal, Quebec · NCT05994976

• Evaluating Deucravacitinib for Pediatric Plaque Psoriasis

  This study is testing a new medication called Deucravacitinib to see if it helps children and teens with moderate to severe plaque psoriasis feel better and is safe for them to use.

  Recruiting at 45 sites Phase 3 Bristol-Myers Squibb · Ciudad Autonoma de Buenos Aires, Buenos Aires and 64 other locations · NCT04772079

• Evaluating the effects of stopping ixekizumab treatment in plaque psoriasis patients

  This study is testing what happens to people with moderate to severe plaque psoriasis after they stop taking ixekizumab treatment to see how it affects their skin, relapse rates, and overall quality of life over two years.

  Recruiting Phase 4 Singapore General Hospital · Outram Park · NCT04537689

• Combining triamcinolone and vitamin D for treating psoriasis

  This study is testing if using a cream with triamcinolone and taking vitamin D3 can help people with mild to moderate psoriasis feel better.

  Recruiting Early Phase 1 Wright State University · Fairborn, Ohio · NCT04036188

Related topics

Quick answers

How many Plaque Psoriasis clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in China (9 trials), Canada (7 trials), Spain (6 trials), Germany (5 trials), United States (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 6, Phase 1: 2, Phase 2: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →